Ok_老虎社区_美港股上老虎

GinC
2021-11-26

UPDATE 1-India's Serum Institute resumes vaccine exports under COVAX facility

(Adds background, details on exports) BENGALURU, Nov 26 (Reuters) - Serum Institute of India $(SII

UPDATE 1-India's Serum Institute resumes vaccine exports under COVAX facility

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":877643088,"tweetId":"877643088","gmtCreate":1637929482972,"gmtModify":1637929483046,"author":{"id":3567228558278395,"idStr":"3567228558278395","authorId":3567228558278395,"authorIdStr":"3567228558278395","name":"GinC","avatar":"https://static.tigerbbs.com/e4cc69cd9347bbc54a06cbaf34fc2745","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/877643088","repostId":2186106763,"repostType":2,"repost":{"id":"2186106763","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1637927426,"share":"https://ttm.financial/m/news/2186106763?lang=&edition=full","pubTime":"2021-11-26 19:50","market":"us","language":"en","title":"UPDATE 1-India's Serum Institute resumes vaccine exports under COVAX facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2186106763","media":"Reuters","summary":"(Adds background, details on exports)   BENGALURU, Nov 26 (Reuters) - Serum Institute of India $(SII","content":"<html><body><p>(Adds background, details on exports)</p><p>   BENGALURU, Nov 26 (Reuters) - Serum Institute of India <a href=\"https://laohu8.com/S/SII\">$(SII)$</a>, the world's biggest vaccine maker, said on Friday it shipped the first batch of AstraZeneca's COVID-19 vaccine, branded as Covishield, to the COVAX vaccine-sharing programme after an eight-month hiatus.</p><p>   India in March put a temporary hold on all major exports of the AstraZeneca    coronavirus shot made by the family-run firm in order to inoculate its own citizens as the country struggled to manage a devastating surge of COVID-19 cases.</p><p>   The resumption of exports was linked to SII surpassing its original target to produce 1 billion doses of Covishield by the end of the year, the company said </p><p>adding that the total number of vaccine doses produced have crossed 1.25 billion.</p><p>   SII said its supply of doses via COVAX was expected to increase substantially into the first quarter of 2022.</p><p>   To boost its COVID-19 vaccine output further, SII will bring into production other vaccines under licence, including COVOVAX, from U.S.-based Novavax   .</p><p> (Reporting by Shivani Singh and Chris Thomas in Bengaluru; Editing by Shounak Dasgupta)</p><p>((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-India's Serum Institute resumes vaccine exports under COVAX facility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-India's Serum Institute resumes vaccine exports under COVAX facility\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-11-26 19:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds background, details on exports)</p><p>   BENGALURU, Nov 26 (Reuters) - Serum Institute of India <a href=\"https://laohu8.com/S/SII\">$(SII)$</a>, the world's biggest vaccine maker, said on Friday it shipped the first batch of AstraZeneca's COVID-19 vaccine, branded as Covishield, to the COVAX vaccine-sharing programme after an eight-month hiatus.</p><p>   India in March put a temporary hold on all major exports of the AstraZeneca    coronavirus shot made by the family-run firm in order to inoculate its own citizens as the country struggled to manage a devastating surge of COVID-19 cases.</p><p>   The resumption of exports was linked to SII surpassing its original target to produce 1 billion doses of Covishield by the end of the year, the company said </p><p>adding that the total number of vaccine doses produced have crossed 1.25 billion.</p><p>   SII said its supply of doses via COVAX was expected to increase substantially into the first quarter of 2022.</p><p>   To boost its COVID-19 vaccine output further, SII will bring into production other vaccines under licence, including COVOVAX, from U.S.-based Novavax   .</p><p> (Reporting by Shivani Singh and Chris Thomas in Bengaluru; Editing by Shounak Dasgupta)</p><p>((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4135":"资产管理与托管银行","SII":"Sprott Inc","NVAX":"诺瓦瓦克斯医药"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186106763","content_text":"(Adds background, details on exports)   BENGALURU, Nov 26 (Reuters) - Serum Institute of India $(SII)$, the world's biggest vaccine maker, said on Friday it shipped the first batch of AstraZeneca's COVID-19 vaccine, branded as Covishield, to the COVAX vaccine-sharing programme after an eight-month hiatus.   India in March put a temporary hold on all major exports of the AstraZeneca    coronavirus shot made by the family-run firm in order to inoculate its own citizens as the country struggled to manage a devastating surge of COVID-19 cases.   The resumption of exports was linked to SII surpassing its original target to produce 1 billion doses of Covishield by the end of the year, the company said adding that the total number of vaccine doses produced have crossed 1.25 billion.   SII said its supply of doses via COVAX was expected to increase substantially into the first quarter of 2022.   To boost its COVID-19 vaccine output further, SII will bring into production other vaccines under licence, including COVOVAX, from U.S.-based Novavax   . (Reporting by Shivani Singh and Chris Thomas in Bengaluru; Editing by Shounak Dasgupta)((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))","news_type":1,"symbols_score_info":{"NVAX":0.9,"SII":1}},"isVote":1,"tweetType":1,"viewCount":1933,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}